Subchondroplasty Study


We are looking to test a new type of treatment for patients with early knee osteoarthritis. Osteoarthritis occurs due to inflammation in the knee. This inflammation can lead to areas of swollen bone called bone marrow lesions. These bone marrow lesions cause pain and are often associated with osteoarthritis.

There is a new treatment for these bone marrow lesions called subchondroplasty. Subchondroplasty involves injecting a flowable calcium substance into the bone marrow lesion. This injection would occur during minimally-invasive knee surgery. The injected calcium substance will strengthen the swollen bone and help it heal.

We want to determine if subchondroplasty can reduce knee pain and improve knee function. This would involve completing questionnaires and having x-rays, MRI, and CT images taken of your knee before surgery and then at different timepoints up to 2 years after surgery.


Currently recruiting participants: Yes

Eligible gender: Male, Female, Transgender, Other

Eligible ages: 40 to 90

Inclusion criteria:

Inclusion Criteria:
• 40 years of age or older
• Early osteoarthritis with symptoms in the affected knee
• Experiencing pain in the affected knee for at least 3 months
• Lack of response to non-operative treatment
• Intend to undergo surgery to treat the affected knee
• No additional knee injuries affecting either knee

Exclusion criteria:

Exclusion Criteria:
• End-stage osteoarthritis in the affected knee
• Other types of arthritis (rheumatoid arthritis, septic arthritis, reactive arthritis etc)
• Gout
• Restricted knee motion
• Unstable knee
• Severe diabetes
• Sickle cell anemia or autoimmune disease
• History of recent cancer (Unless treated in the past and has had no clinical signs or symptoms of malignancy for 5 years or longer)


Fill out the following form if you want to participate in this research

Method of contact

Additional information

Contact information

Please contact or 403-220-8944 if you have any questions about this criteria and/or to find out more about this study.

Principal investigator:

Alexander Rezansoff

Clinical trial: